Results on efficacy and safety of cancer treatment with or without tumor necrosis factor‑related apoptosis‑inducing ligand‑related agents: a meta-analysis

Sun,Shaoxing; Li,Zonghuan; Sun,Li; Yang,Chunxu; Mei,Zijie; Ouyang,Wen; Yang,Bo; Xie,Conghua

doi:10.3892/mco.2014.261

May-June 2014 Volume 2 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-June 2014 Volume 2 Issue 3

Full Size Image

Article

Results on efficacy and safety of cancer treatment with or without tumor necrosis factor‑related apoptosis‑inducing ligand‑related agents: a meta-analysis

Authors:
- Shaoxing Sun
- Zonghuan Li
- Li Sun
- Chunxu Yang
- Zijie Mei
- Wen Ouyang
- Bo Yang
- Conghua Xie
View Affiliations / Copyright

Affiliations: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Pages: 440-448
|
Published online on: February 18, 2014

https://doi.org/10.3892/mco.2014.261
Expand metrics +

Abstract

This meta‑analysis aimed to evaluate the currently available evidence on the efficacy and safety of cancer treatment with or without tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL)‑related agents. We conducted a systematic search through Medline, Cochrane Library and EMBASE electronic databases and manually searched the Journal of Clinical Oncology to identify randomized controlled trials (RCTs) conducted between 1995 and 2013 comparing the efficacy and safety results of cancer treatment with and without TRAIL‑related agents. The methodological quality of the included RCTs was assessed by the Cochrane Risk of Bias assessment tool. The outcome measurements included objective response rate (ORR), clinical benefit rate (CBR)̸disease control rate (DCR) and adverse events (AEs). The relevant data were analyzed using Review Manager 5.2 software. Grading of Recommendations Assessment Development and Evaluation was used to assess the quality of evidence and grade of recommendation. Four RCTs, including a total of 596 patients, were ultimately selected and analyzed. There were no statistically significant differences among the 4 RCTs regarding ORR [relative risk (RR)=0.92, 95% confidence interval (CI): 0.73‑1.15, P=0.45], CBR̸DCR (RR=0.92, 95% CI: 0.81‑1.05, P=0.21), progression‑free survival [hazard ratio (HR)=0.89, 95% CI: 0.75‑1.05, P=0.16], overall survival (HR=0.90, 95% CI: 0.74‑1.09, P=0.27), number of patients with any AEs (RR=0.99, 95% CI: 0.96‑1.03, P=0.77), number of patients with any severe AEs (RR=0.95, 95% CI: 0.78‑1.55, P=0.58), number of patients with ≥grade 3 AEs (RR=1.13, 95% CI: 0.93‑1.38, P=0.22) and number of fatal AEs (RR=1.14, 95% CI: 0.71‑1.81, P=0.59). The quality of evidence was considered to be moderate and the recommendation grades were weak. In conclusion, the benefits of TRAIL‑related agents in the treatment of cancer patients remain uncertain and further clinical trials are required.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2.	Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
3.	Pitti RM, Marsters SA, Ruppert S, et al: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
4.	Pan G, O’Rourke K, Chinnaiyan AM, et al: The receptor for the cytotoxic ligand TRAIL. Science. 276:111–113. 1997. View Article : Google Scholar : PubMed/NCBI
5.	Pan G, Ni J, Wei YF, et al: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:815–818. 1997. View Article : Google Scholar : PubMed/NCBI
6.	Rowinsky EK: Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 23:9394–9407. 2005. View Article : Google Scholar
7.	Marsters SA, Sheridan JP, Pitti RM, et al: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 7:1003–1006. 1997. View Article : Google Scholar : PubMed/NCBI
8.	Ashkenazi A, Holland P and Eckhardt SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 26:3621–3630. 2008. View Article : Google Scholar
9.	Bellail AC, Qi L, Mulligan P, et al: TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials. 4:34–41. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Higgins JPT and Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. 2011, https://www.cochrane-handbook.org Accessed, September 20, 2013.
11.	Schunemann H, Brozek J and Oxman A: GRADE handbook for grading the quality of evidence and the strength of recommendations Version 3.2 (updated March 2009). GRADE Working Group. 2009, Available from http:/www.cc-ims.net/gradepro. Accessed September 20, 2013.
12.	Tierney JF, Stewart LA, Ghersi D, et al: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
13.	Soria JC, Mark Z, Zatloukal P, et al: Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol. 29:4442–4451. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Demetri GD, Le Cesne A, Chawla SP, et al: First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer. 48:547–563. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Kindler HL, Richards DA, Garbo LE, et al: A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 23:2834–2842. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Paz-Ares L, Balint B, de Boer RH, et al: A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 8:329–337. 2013.PubMed/NCBI
17.	Plummer R, Attard G, Pacey S, et al: Phase 1 and pharmaco-kinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res. 13:6187–6194. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Tolcher AW, Mita M, Meropol NJ, et al: Phase I pharmaco-kinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 25:1390–1396. 2007. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Results on efficacy and safety of cancer treatment with or without tumor necrosis factor‑related apoptosis‑inducing ligand‑related agents: a meta-analysis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Related Articles